# Cocaine
*Source: https://go.drugbank.com/drugs/DB00907*

## Overview

### Description

This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.

### Background

An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.

### Indication

For the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.

### Pharmacodynamics

Cocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.

### Mechanism of Action

Sodium-dependent dopamine transporter
Inhibitor
Sodium-dependent noradrenaline transporter
Inhibitor
Sodium channel protein
Inhibitor
+ 1 more target

### Absorption

Cocaine is absorbed from all sites of application, including mucous membranes and gastrointestinal mucosa. By oral or intra-nasal route, 60 to 80% of cocaine is absorbed.

### Metabolism

Hepatic. Cocaine is metabolized to benzoylecgonine and ecgonine methyl ester, which are both excreted in the urine. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself.
Hover over products below to view reaction partners
Cocaine
norcocaine
Benzoylecgonine
Cocaethylene

### Half-life

1 hour

### Toxicity

Intense agitation, convulsions, hypertension, rhythm disturbance, coronary insufficiency, hyperthermia, rhabdomyolysis, and renal impairment. Oral mouse LD
50
= 96 mg/kg

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Abametapir
The serum concentration of Cocaine can be increased when it is combined with Abametapir.
Abemaciclib
The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Cocaine.
Abiraterone
The risk or severity of methemoglobinemia can be increased when Abiraterone is combined with Cocaine.
Acebutolol
The metabolism of Acebutolol can be decreased when combined with Cocaine.
Acetaminophen
The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Cocaine.

### Food Interactions

No interactions found.

## Chemical Information

**DrugBank ID:** DB00907

**Synonyms:** (-)-Cocaine
(−)-cocaine
[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
2-methyl-3β-hydroxy-1αH,5αH-tropane-2β-carboxylate benzoate (ester)
Benzoylmethylecgonine
beta-Cocain
Cocain
Cocaina
Cocaine
Cocainum
Kokain
L-Cocain
L-Cocaine
methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl benzoylecgonine
Neurocaine

**Chemical Formula:** C
17
H
21
NO
4

**SMILES:** [H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C

**Weight:** Average: 303.3529
Monoisotopic: 303.147058165

**IUPAC Name:** methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US9867815
No
2018-01-16
2037-02-07
US
US10016407
No
2018-07-10
2037-02-07
US
US10149843
No
2018-12-11
2037-02-07
US
US10231961
No
2019-03-19
2037-02-07
US
US10413505
No
2019-09-17
2037-02-07
US
US10420760
No
2019-09-24
2037-02-07
US
US10857095
No
2020-12-08
2037-02-07
US
US10894012
No
2021-01-19
2037-02-07
US
US10933060
No
2021-03-02
2037-02-07
US
US10973811
No
2021-04-13
2037-02-07
US
US10987347
No
2021-04-27
2037-02-07
US
US11040032
No
2021-06-22
2037-02-07
US

### Indicated Conditions

2

### Phase 0

7

### Phase 1

33

### Phase 2

12

### Phase 3

6

### Phase 4

5

### Therapeutic Categories

Anesthetics,
Local
Local Anesthetics
(Ester)

### Summary

Cocaine
is an ester local anesthetic used during diagnostic procedures and surgeries in or through the nasal cavities.

### Brand Names

Goprelto, Numbrino

### Generic Name

Cocaine

### DrugBank Accession Number

DB00907

### Groups

Approved, Illicit, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Cocaine (DB00907)
×
Close

### External IDs

IDS-NC-004
RX-0041
RX0041

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Create Account

### Mechanism of action

Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine.
Target
Actions
Organism
A
Sodium-dependent dopamine transporter
inhibitor
Humans
A
Sodium-dependent noradrenaline transporter
inhibitor
Humans
A
Sodium channel protein
inhibitor
Humans
A
Sodium-dependent serotonin transporter
inhibitor
Humans
U
Muscarinic acetylcholine receptor M1
antagonist
Humans
U
Muscarinic acetylcholine receptor M2
antagonist
Humans
U
Sigma non-opioid intracellular receptor 1
agonist
Humans
U
Liver carboxylesterase 1
binder
Humans

### Pathways

Pathway
Category
Cocaine Action Pathway
Drug action

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Cocaine hydrochloride
XH8T8T6WZH
53-21-4
PIQVDUKEQYOJNR-VZXSFKIWSA-N

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Cocaine Hydrochloride
Solution
100 mg/1mL
Topical
Lannett Company, Inc.
2008-12-01
2020-08-31
US
Cocaine Hydrochloride
Solution
40 mg/1mL
Topical
Lannett Company, Inc.
2008-12-01
2020-08-31
US
Cocaine Hydrochloride Top Sol 40mg/ml
Liquid
40 mg / mL
Topical
Sandoz S.P.A.
1992-12-31
2019-08-01
Canada
Cocaine Hydrochloride Topical Sol 10%
Liquid
100 mg / mL
Topical
Sandoz S.P.A.
1992-12-31
2019-08-01
Canada
Goprelto
Solution
40 mg/1mL
Nasal
LXO US Inc.
2024-02-09
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Cocaine Hydrochloride
Solution
40 mg/1mL
Nasal
Genus Lifesciences Inc.
2018-06-04
Not applicable
US
Cocaine Hydrochloride
Solution
40 mg/1mL
Nasal
LXO US Inc.
2024-01-29
Not applicable
US
Cocaine Hydrochloride Nasal
Solution
40 mg/1mL
Topical
OMNIVIUM PHARMACEUTICALS LLC.
2023-10-15
Not applicable
US
Cocaine Hydrochloride Nasal
Solution
40 mg/1mL
Topical
Lannett Company, Inc.
2020-01-10
2024-08-31
US
PMS-cocaine Hydrochloride Topical Sol 10%
Liquid
100 mg / mL
Topical
Pharmascience Inc
1995-12-31
Not applicable
Canada

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Cocaine Hydrochloride
Cocaine hydrochloride
(100 mg/1mL)
Solution
Topical
Lannett Company, Inc.
2008-12-01
2020-08-31
US
Cocaine Hydrochloride
Cocaine hydrochloride
(40 mg/1mL)
Solution
Topical
Lannett Company, Inc.
2008-12-01
2020-08-31
US

### ATC Codes

S01HA01 — Cocaine
S01HA — Local anesthetics
S01H — LOCAL ANESTHETICS
S01 — OPHTHALMOLOGICALS
S — SENSORY ORGANS
S02DA02 — Cocaine
S02DA — Analgesics and anesthetics
S02D — OTHER OTOLOGICALS
S02 — OTOLOGICALS
S — SENSORY ORGANS
N01BC01 — Cocaine
N01BC — Esters of benzoic acid
N01B — ANESTHETICS, LOCAL
N01 — ANESTHETICS
N — NERVOUS SYSTEM
R02AD03 — Cocaine
R02AD — Anesthetics, local
R02A — THROAT PREPARATIONS
R02 — THROAT PREPARATIONS
R — RESPIRATORY SYSTEM

### Drug Categories

Agents producing tachycardia
Agents that reduce seizure threshold
Alkaloids
Analgesics and Anesthetics
Anesthetics
Anesthetics, Local
Anticholinergic Agents
Aza Compounds
Azabicyclo Compounds
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Stimulants
Cholinesterase substrates
Cocaine, antagonists & inhibitors
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Dopamine Agents
Dopamine Uptake Inhibitors
Esters of Benzoic Acid
Highest Risk QTc-Prolonging Agents
Local Anesthetics (Ester)
Membrane Transport Modulators
Muscarinic Antagonists
Nervous System
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
OCT2 Inhibitors
Ophthalmologicals
QTc Prolonging Agents
Sensory Organs
Sensory System Agents
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Throat Preparations
Tropanes
Vasoconstrictor Agents

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Tropane alkaloids
/
Piperidinecarboxylic acids
/
Benzoyl derivatives
/
N-alkylpyrrolidines
/
Dicarboxylic acids and derivatives
/
Methyl esters
/
Trialkylamines
/
Amino acids and derivatives
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 3 more
Substituents
Amine
/
Amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Benzoate ester
/
Benzoyl
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Dicarboxylic acid or derivatives
/
Hydrocarbon derivative
/
Methyl ester
/
N-alkylpyrrolidine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperidine
/
Piperidinecarboxylic acid
/
Pyrrolidine
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tropane alkaloid
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, tropane alkaloid, methyl ester, benzoate ester (
CHEBI:27958
)
/
Tropane alkaloids, Alkaloids (
C01416
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Benzoic acids and derivatives

### Direct Parent

Benzoic acid esters

### Alternative Parents

Tropane alkaloids
/
Piperidinecarboxylic acids
/
Benzoyl derivatives
/
N-alkylpyrrolidines
/
Dicarboxylic acids and derivatives
/
Methyl esters
/
Trialkylamines
/
Amino acids and derivatives
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 3 more

### Substituents

Amine
/
Amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Azacycle
/
Benzoate ester
/
Benzoyl
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Dicarboxylic acid or derivatives
/
Hydrocarbon derivative
/
Methyl ester
/
N-alkylpyrrolidine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperidine
/
Piperidinecarboxylic acid
/
Pyrrolidine
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tropane alkaloid
show 16 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

tertiary amino compound, tropane alkaloid, methyl ester, benzoate ester (
CHEBI:27958
)
/
Tropane alkaloids, Alkaloids (
C01416
)

### Affected organisms

Humans and other mammals

### UNII

I5Y540LHVR

### CAS number

50-36-2

### InChI Key

ZPUCINDJVBIVPJ-LJISPDSOSA-N

### InChI

InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1

### Synthesis Reference

Nobuyuki Shigetoh, Hiroshi Nakayama, Jinsei Miyazaki, Tadayasu Mitsumata, "Labelling colors for detecting cocaine or methamphetamine, method of preparing the same and detector for cocaine or methamphetamine." U.S. Patent US5571727, issued October, 1981.
US5571727

### General References

Siegel RK, Elsohly MA, Plowman T, Rury PM, Jones RT: Cocaine in herbal tea. JAMA. 1986 Jan 3;255(1):40. [
Article
]
Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D, Franceschi M, Logan J, Gatley SJ, Wong C, Ding YS, Hitzemann R, Pappas N: Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000 Aug 11;67(12):1507-15. [
Article
]
Dimitrijevic N, Dzitoyeva S, Manev H: An automated assay of the behavioral effects of cocaine injections in adult Drosophila. J Neurosci Methods. 2004 Aug 30;137(2):181-4. [
Article
]
Uz T, Akhisaroglu M, Ahmed R, Manev H: The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice. Neuropsychopharmacology. 2003 Dec;28(12):2117-23. [
Article
]
McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, Nestler EJ: Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9377-81. Epub 2005 Jun 20. [
Article
]
FDA Approved Products: Numbrino (cocaine hydrochloride) nasal solution [
Link
]
FDA Approved Products: Goprelto (cocaine hydrochloride) nasal solution [
Link
]
DailyMed: Cocaine hydrochloride solution [
Link
]

### External Links

Human Metabolome Database
HMDB0015043
KEGG Drug
D00110
KEGG Compound
C01416
PubChem Compound
446220
PubChem Substance
46506326
ChemSpider
10194104
BindingDB
22418
RxNav
2653
ChEBI
27958
ChEMBL
CHEMBL370805
ZINC
ZINC000003875336
Therapeutic Targets Database
DAP000834
PharmGKB
PA449072
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
COC
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cocaine

### Human Metabolome Database

HMDB0015043

### KEGG Drug

D00110

### KEGG Compound

C01416

### PubChem Compound

446220

### PubChem Substance

46506326

### ChemSpider

10194104

### BindingDB

22418

### RxNav

2653

### ChEBI

27958

### ChEMBL

CHEMBL370805

### ZINC

ZINC000003875336

### Therapeutic Targets Database

DAP000834

### PharmGKB

PA449072

### Guide to Pharmacology

GtP Drug Page

### PDBe Ligand

COC

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Cocaine

### PDB Entries

1i7z
/
1q72
/
2ajv
/
2pgz
/
4xp4
/
4xpb
/
8de3
/
9eo4

### MSDS

Download
(104 KB)

### Packagers

Cody Laboratories Inc.
Lannett Co. Inc.
Mallinckrodt Inc.
Roxane Labs

### Dosage Forms

Form
Route
Strength
Solution
Topical
100 mg/1mL
Solution
Topical
40 mg/1mL
Liquid
Topical
40 mg / mL
Liquid
Topical
100 mg / mL
Solution
Nasal
40 mg/1mL

### Prices

Unit description
Cost
Unit
Cocaine hydrochloride powder
68.44USD
g
Cocaine 10% solution
10.68USD
ml
Cocaine 4% solution
6.22USD
ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
98 °C
PhysProp
water solubility
1800 mg/L (at 22 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP
2.30
HANSCH,C ET AL. (1995)
logS
-2.23
ADME Research, USCD
pKa
8.61 (at 15 °C)
MERCK INDEX (1996)

### Predicted Properties

Property
Value
Source
Water Solubility
5.03 mg/mL
ALOGPS
logP
1.97
ALOGPS
logP
2.28
Chemaxon
logS
-1.8
ALOGPS
pKa (Strongest Basic)
8.85
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
55.84 Å
2
Chemaxon
Rotatable Bond Count
5
Chemaxon
Refractivity
81.16 m
3
·mol
-1
Chemaxon
Polarizability
32.02 Å
3
Chemaxon
Number of Rings
3
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.8644
Blood Brain Barrier
+
0.8805
Caco-2 permeable
+
0.7654
P-glycoprotein substrate
Substrate
0.5
P-glycoprotein inhibitor I
Inhibitor
0.8168
P-glycoprotein inhibitor II
Non-inhibitor
0.893
Renal organic cation transporter
Inhibitor
0.6182
CYP450 2C9 substrate
Non-substrate
0.7897
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Substrate
0.6856
CYP450 1A2 substrate
Non-inhibitor
0.8627
CYP450 2C9 inhibitor
Non-inhibitor
0.9341
CYP450 2D6 inhibitor
Non-inhibitor
0.5614
CYP450 2C19 inhibitor
Non-inhibitor
0.9383
CYP450 3A4 inhibitor
Non-inhibitor
0.9237
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9408
Ames test
Non AMES toxic
0.7437
Carcinogenicity
Non-carcinogens
0.9585
Biodegradation
Not ready biodegradable
0.5319
Rat acute toxicity
2.6387 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8463
hERG inhibition (predictor II)
Non-inhibitor
0.8042
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(2.96 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0a5a-9620000000-fd84236e0a4ca8f55456
GC-MS Spectrum - EI-B
GC-MS
splash10-001i-9200000000-5262d40bbcdec08759ab
GC-MS Spectrum - CI-B
GC-MS
splash10-0udi-0109000000-319d789d066a157a0966
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-0udi-0009000000-a2004e33ce1140fd0ed1
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-0f89-0908000000-b5abe87da56f09f21f65
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-001i-0900000000-ee9c7f3b491476f49e98
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-001i-0900000000-2dab4b98f61ec4ba2467
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-0fz9-0900000000-b3c61e257fbaf700b52b
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-3b1dc1a8c8390bfb6c3e
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-0udi-0009000000-0479d3211208134ed140
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-0ue9-0709000000-d19680d406708cbbc59b
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-1900000000-5ac8f8a2719f70332b86
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-3900000000-5ff2f6c28b5db03035be
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-053r-8900000000-e597f9f6f5014d501e62
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-0a5c-9500000000-0fcf099229f148719078
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-0udi-0009000000-ee11934dd1158606bb84
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-0ue9-0609000000-bd90cd1f98ce1845ba6b
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-1900000000-9fc49ca16ab794b8c37d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-3900000000-cb0b593e7f379f7c6aef
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-053r-8900000000-2a88bad614aed29eac52
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-0a59-9500000000-c9713abdcf52a45d6ed2
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-c18cf276038cf1946f20
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0udi-0429000000-98e2928cd21fb2234d5b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0fk9-0904000000-d5219fa2ebf7d3ed8fd3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0fk9-0982000000-9601082e7300a30880e8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00di-0900000000-985a213761c9d9403ae7
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00di-3951000000-8fd09875f58791075b1f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00b9-9721000000-4d8187110632b8ce6a55
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
174.4089035
predicted
DarkChem Lite v0.1.0
[M-H]-
173.6360035
predicted
DarkChem Lite v0.1.0
[M-H]-
170.43347
predicted
DeepCCS 1.0 (2019)
[M+H]+
173.1699035
predicted
DarkChem Lite v0.1.0
[M+H]+
173.3030035
predicted
DarkChem Lite v0.1.0
[M+H]+
172.82906
predicted
DeepCCS 1.0 (2019)
[M+Na]+
173.5483035
predicted
DarkChem Lite v0.1.0
[M+Na]+
173.1510035
predicted
DarkChem Lite v0.1.0
[M+Na]+
179.20958
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

No

### Actions

Inhibitor

### General Function

Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)

### Specific Function

amine binding

### Gene Name

SLC6A3

### Uniprot ID

Q01959

### Uniprot Name

Sodium-dependent dopamine transporter

### Molecular Weight

68494.255 Da

### Curator comments

Data suggest that cocaine is a weak inhibitor.

